Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2003
06/04/2003EP1315509A2 Treatment of drug resistant organisms with nitric oxide
06/04/2003EP1315503A1 Treatment of urinary dysfunction
06/04/2003EP1315502A1 Method for treating erectile dysfunction and increasing libido in men
06/04/2003EP1315501A1 Alpha v integrin receptor antagonists
06/04/2003EP1315500A1 Pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
06/04/2003EP1315499A1 Compositions and methods for the treatment of anorectal disorders
06/04/2003EP1315494A1 Agent for modulating excitatory synaptic transmission comprising a compound having alpha-7 nicotinic acetylcholine receptor activation property
06/04/2003EP1315486A2 Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
06/04/2003EP1315476A2 Nitric oxide-producing hydrogel materials
06/04/2003EP1315475A1 Lung surfactant compositions with dynamic swelling behaviour
06/04/2003EP1315417A2 Mutant non-human mammal for expressing the alpha6 acetylcholine nicotinic receptor subunit and use for screening substances capable of interacting with said receptor
06/04/2003EP1216046B1 Novel combination of loteprednol and antihistamines
06/04/2003EP1200099B1 Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds
06/04/2003EP1156790B1 Combinations of formoterol and mometasone furoate
06/04/2003EP1143997B1 Tumor necrosis factor antagonists and their use in endometriosis treatment
06/04/2003EP1140186B1 Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
06/04/2003EP1140185B1 Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
06/04/2003EP1140184B1 Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
06/04/2003EP1105390B1 Imidazo[1,2-a]pyridine derivatives for the treatment of gastrointestinal diseases
06/04/2003EP1017395A4 Method for treating premenstrual or late luteal phase syndrome
06/04/2003EP0969821B1 Pellets having a core coated with an antifungal and a polymer
06/04/2003EP0967987B1 Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
06/04/2003EP0910357B1 Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression
06/04/2003EP0858329B1 Novel stable liquid paracetamol compositions, and method for preparing same
06/04/2003EP0814839B1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
06/04/2003EP0789578B1 Multicatalytic protease inhibitors
06/04/2003EP0782450B1 Use of aromatase inhibitors in the preparation of a drug for treating a relative androgen deficiency in men
06/04/2003EP0656007B1 Delta opioid receptor genes
06/04/2003CN1422281A G-protein coupled receptors
06/04/2003CN1422246A Malonamic acids and derivatives thereof as thyroid receptor ligands
06/04/2003CN1422230A Infusion packet with useful and decorative element, support member, delivery system and method
06/04/2003CN1422162A Composition and method for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant
06/04/2003CN1422161A New combination of a beta blocker and a cholesterol-lowering agent
06/04/2003CN1422158A Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response
06/04/2003CN1422157A Divided dose therapies with vascular damaging activity
06/04/2003CN1422156A Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
06/04/2003CN1422154A The treatment of respiratory diseases
06/04/2003CN1422153A Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
06/04/2003CN1422152A Combination of organic compound
06/04/2003CN1422148A Method for treating dry eye
06/04/2003CN1422146A Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials
06/04/2003CN1422142A Pharmaceutical composition
06/04/2003CN1421197A Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology
06/04/2003CN1421196A Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology
06/04/2003CN1421195A Composition containing N-vinyl iminazole polymer of copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology
06/04/2003CN1421194A Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology
06/04/2003CN1421193A Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology
06/04/2003CN1110553C Gene engineering adenovirus and it application
06/04/2003CN1110302C Oxyacid and related compounds for treating skin disease
06/03/2003US6573302 Topical carrier wherein the topical carrier comprises a member selected from the group comprising lavender oil, myristal myristate, and other preservatives including, hypericum perforatum arnica montana capric acid; and capsaicin and
06/03/2003US6573299 Method and compositions for treatment of the aging eye
06/03/2003US6573290 DFMO and celecoxib in combination for cancer chemoprevention and therapy
06/03/2003US6573287 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
06/03/2003US6573280 Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent
06/03/2003US6573271 Following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome
06/03/2003US6573262 Compounds for treating mammals infected with HIV virus
06/03/2003US6573253 Methods for the administration of amifostine and related compounds
06/03/2003US6573096 Continuous cell lines which produce monospecific antibodies that specifically bind an epitope of a human dipeptidyl peptidase IV and thereby inhibit angiogenesis; use in treatment of cancer
06/03/2003US6573079 Methods and interferon deficient substrates for the propagation of viruses
06/03/2003US6573067 Nucleic acid encoding sodium channels in dorsal root ganglia
06/03/2003US6573063 Methods and systems for assessing biological materials using optical and spectroscopic detection techniques
06/03/2003US6572898 Electrolyte gels for maintaining hydration and rehydration
06/03/2003US6572895 Treatment of congestive heart failure
06/03/2003US6572893 Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
06/03/2003US6572880 Methods and transdermal compositions for pain relief
06/03/2003US6572871 Pain treatment method and apparatus using heating wrap and analgesic cream
06/03/2003US6572858 Uses for anti-malarial therapeutic agents
06/03/2003US6572841 Composition and method for decreasing upper respiratory airway resistance
06/03/2003US6572638 Method of controlling body temperature while inhibiting thermoregulatory responses
06/03/2003CA2413491A1 Treatment for ischemic stroke
05/2003
05/30/2003WO2003044524A2 Methods and means for influencing intracellular communication and intracellular organelle transport
05/30/2003WO2003044184A1 Treatment of pml targeting jc virus agno
05/30/2003WO2003044172A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3
05/30/2003WO2003044170A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/30/2003WO2003044162A2 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003WO2003043980A1 Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
05/30/2003WO2003043966A2 Clusianon isomers and use thereof
05/30/2003WO2003043905A2 Pharmaceutical product with an adsorbent
05/30/2003WO2003043669A1 Composition and method for treatment of wounds
05/30/2003WO2003043668A2 Conditioning solution for contact lenses
05/30/2003WO2003043658A1 Anti-proliferative composition
05/30/2003WO2003043657A1 Topical delivery of codrugs
05/30/2003WO2003043656A1 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug
05/30/2003WO2003043649A1 Removal promoters and inhibitor for apoptosis cells in vivo
05/30/2003WO2003043647A2 A plant extract active as an immunostimulating agent
05/30/2003WO2003043640A2 Treatment of major depressive disorder using glucocorticoid receptor antagonists
05/30/2003WO2003043639A2 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER
05/30/2003WO2003043628A1 Medicament for the treatment of viral skin and tumour diseases
05/30/2003WO2003043624A1 Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
05/30/2003WO2003043622A1 Substituted bicyclo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients
05/30/2003WO2003043621A1 Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
05/30/2003WO2003043619A1 New use for the treatment of gastroesophageal reflux disease
05/30/2003WO2003043617A1 Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof
05/30/2003WO2003043615A2 Hypertonia treatment during the acute phase of a cerebrovascular accident
05/30/2003WO2003043613A2 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
05/30/2003WO2003043606A1 Pharmaceutical formulation comprising bicalutamide
05/30/2003WO2003043591A1 Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation
05/30/2003WO2003043576A2 Flowable osteogenic and chondrogenic compositions
05/30/2003WO2003043572A2 Methods and compositions related to irm compounds and toll-like receptor pathways
05/30/2003WO2003043570A2 Formulations and methods for treatment or amelioration of inflammatory conditions
1 ... 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 ... 1151